Protocol Ledger

NCT04929028 · Phase II · ACTIVE NOT RECRUITING

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Interventional Phase II clinical trial protocol NCT04929028 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-09 Enrollment: 40 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04929028
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)40 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04929028
Protocol FieldVerified Registry Value
NCT IdentifierNCT04929028
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment40 participants (ESTIMATED)
Registered Start Date2022-08-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI